ArticleBiomedica : revista del Instituto Nacional de Salud2026
Dramatic increase in consumption of antibiotics in Colombia, 2020-2023
Article in Biomedica : revista del Instituto Nacional de Salud, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntibiotic consumption and resistance have increased worldwide. Antibiotic resistance results in longer hospital stays and higher healthcare costs.
objectiveTo describe the consumption of antibiotics and associated expenses in Colombia. MATERIALS AND
methodsA meticulous descriptive cross-sectional study of antibiotic consumption and expenditure in Colombia from 2020 to 2023 was conducted. Between 2020 and 2023, a description of the consumption and expenditure of antibiotics in Colombia was made. Data were obtained from IQVIA™ (IMS Health and Quintiles). The prominent families of antimicrobials used in Colombia were selected. Twelve pharmacological families were classified, including 27 antimicrobials and three β-lactamase inhibitors. The defined daily dose was used to measure antibiotic consumption, identify variations, and evaluate medical prescription practices. The defined daily dose per 1,000 inhabitants per day was estimated to obtain information from the population receiving daily antibiotic treatment. The amount of antibiotics used was estimated in grams and tons per year.
resultsThe top 10 most consumed antimicrobials by defined daily dose per 1,000 inhabitants per day in Colombia were amoxicillin, azithromycin, metronidazole, cephalexin, ciprofloxacin, trimethoprim-sulfamethoxazole, ampicillin, sulbactam, clarithromycin, cefazolin, and dicloxacillin. The total consumption of antibiotics was 2,139 tons, which represented an expense of USD$ 708,112,587, for an increase of 17 and 8%, respectively, during the period.
conclusionsThe progressive increase in consumption and spending on antimicrobials in Colombia requires a set of interventions that include promoting changes in medical prescribing behaviour and a public education campaign that leads to the adoption of a sustainable public health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.